Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients

This study explored circulating miRNAs and target genes associated with metabolic syndrome (MetS) and cardiometabolic risk in obese patients. Small-RNA sequencing was used to assess the peripheral blood miRNome of 12 obese subjects (6 MetS and 6 non-MetS). Differentially expressed miRNAs and target...

Full description

Bibliographic Details
Main Authors: Alvaro Cerda, Adonai Aralim Amaral, Raquel de Oliveira, Tamiris Invencioni Moraes, Aécio Assunção Braga, Magda Elizabeth Graciano-Saldarriaga, Cristina Moreno Fajardo, Thiago Dominguez Crespo Hirata, Vivian Bonezi, Antony Brayan Campos-Salazar, Egidio Lima Dorea, Marcia Martins Silveira Bernik, Mario Hiroyuki Hirata, Rosario Dominguez Crespo Hirata
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/22/3/1468
id doaj-f6d4524293314a7ea2b962f43df1c7e5
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Alvaro Cerda
Adonai Aralim Amaral
Raquel de Oliveira
Tamiris Invencioni Moraes
Aécio Assunção Braga
Magda Elizabeth Graciano-Saldarriaga
Cristina Moreno Fajardo
Thiago Dominguez Crespo Hirata
Vivian Bonezi
Antony Brayan Campos-Salazar
Egidio Lima Dorea
Marcia Martins Silveira Bernik
Mario Hiroyuki Hirata
Rosario Dominguez Crespo Hirata
spellingShingle Alvaro Cerda
Adonai Aralim Amaral
Raquel de Oliveira
Tamiris Invencioni Moraes
Aécio Assunção Braga
Magda Elizabeth Graciano-Saldarriaga
Cristina Moreno Fajardo
Thiago Dominguez Crespo Hirata
Vivian Bonezi
Antony Brayan Campos-Salazar
Egidio Lima Dorea
Marcia Martins Silveira Bernik
Mario Hiroyuki Hirata
Rosario Dominguez Crespo Hirata
Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients
International Journal of Molecular Sciences
obesity
metabolic syndrome
microRNAs
miR-155
<i>CEBPB</i>
cardiometabolic risk
author_facet Alvaro Cerda
Adonai Aralim Amaral
Raquel de Oliveira
Tamiris Invencioni Moraes
Aécio Assunção Braga
Magda Elizabeth Graciano-Saldarriaga
Cristina Moreno Fajardo
Thiago Dominguez Crespo Hirata
Vivian Bonezi
Antony Brayan Campos-Salazar
Egidio Lima Dorea
Marcia Martins Silveira Bernik
Mario Hiroyuki Hirata
Rosario Dominguez Crespo Hirata
author_sort Alvaro Cerda
title Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients
title_short Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients
title_full Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients
title_fullStr Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients
title_full_unstemmed Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients
title_sort peripheral blood mirome identified mir-155 as potential biomarker of mets and cardiometabolic risk in obese patients
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-02-01
description This study explored circulating miRNAs and target genes associated with metabolic syndrome (MetS) and cardiometabolic risk in obese patients. Small-RNA sequencing was used to assess the peripheral blood miRNome of 12 obese subjects (6 MetS and 6 non-MetS). Differentially expressed miRNAs and target genes were further analyzed by qPCR in a larger sample of obese patients (48 MetS and 32 non-MetS). miRNA:mRNA interactions were studied using in silico tools. miRNome analysis identified 10 downregulated miRNAs in MetS compared to non-Met patients (<i>p</i> < 0.05). In silico studies revealed three miRNAs (miR-155, miR-181a, and let-7a) and their predictive targets (CCAAT/enhancer-binding protein beta—<i>CEBPB</i>, KRAS proto-oncogene, GTPase—<i>KRAS</i> and suppressor of cytokine signaling 1—<i>SOCS1</i>) with a potential role in the insulin receptor signaling pathway. miR-155 expression was reduced and <i>CEBPB</i> mRNA levels were increased in MetS patients (<i>p</i> < 0.05), and these effects were correlated with the number of MetS diagnostic criteria (<i>p</i> < 0.05). Increased HOMA-IR (>7.6) was associated with low miR-155 levels, high <i>CEBPB</i> expression, and serum hsCRP (<i>p</i> < 0.05). miR-155 was negatively correlated with <i>CEBPB</i>, HOMA-IR, and plasma fibrinogen, and positively correlated with serum adiponectin (<i>p</i> < 0.05). Downregulation of circulating miR-155 is associated with insulin resistance, poor glycemic control, and increased MetS-related cardiometabolic risk, and these effects are potentially mediated by interaction with <i>CEBPB.</i>
topic obesity
metabolic syndrome
microRNAs
miR-155
<i>CEBPB</i>
cardiometabolic risk
url https://www.mdpi.com/1422-0067/22/3/1468
work_keys_str_mv AT alvarocerda peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT adonaiaralimamaral peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT raqueldeoliveira peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT tamirisinvencionimoraes peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT aecioassuncaobraga peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT magdaelizabethgracianosaldarriaga peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT cristinamorenofajardo peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT thiagodominguezcrespohirata peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT vivianbonezi peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT antonybrayancampossalazar peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT egidiolimadorea peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT marciamartinssilveirabernik peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT mariohiroyukihirata peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
AT rosariodominguezcrespohirata peripheralbloodmiromeidentifiedmir155aspotentialbiomarkerofmetsandcardiometabolicriskinobesepatients
_version_ 1724290464704626688
spelling doaj-f6d4524293314a7ea2b962f43df1c7e52021-02-03T00:01:02ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-02-01221468146810.3390/ijms22031468Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese PatientsAlvaro Cerda0Adonai Aralim Amaral1Raquel de Oliveira2Tamiris Invencioni Moraes3Aécio Assunção Braga4Magda Elizabeth Graciano-Saldarriaga5Cristina Moreno Fajardo6Thiago Dominguez Crespo Hirata7Vivian Bonezi8Antony Brayan Campos-Salazar9Egidio Lima Dorea10Marcia Martins Silveira Bernik11Mario Hiroyuki Hirata12Rosario Dominguez Crespo Hirata13Center of Excellence in Translational Medicine, CEMT-BIOREN & Department of Basic Sciences, Universidad de La Frontera, Av. Alemania 0458, Temuco 4810296, ChileDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilUniversity Hospital, University of Sao Paulo, Av. Prof. Lineu Prestes 2565, Sao Paulo 05508-000, BrazilUniversity Hospital, University of Sao Paulo, Av. Prof. Lineu Prestes 2565, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes 580, Sao Paulo 05508-000, BrazilThis study explored circulating miRNAs and target genes associated with metabolic syndrome (MetS) and cardiometabolic risk in obese patients. Small-RNA sequencing was used to assess the peripheral blood miRNome of 12 obese subjects (6 MetS and 6 non-MetS). Differentially expressed miRNAs and target genes were further analyzed by qPCR in a larger sample of obese patients (48 MetS and 32 non-MetS). miRNA:mRNA interactions were studied using in silico tools. miRNome analysis identified 10 downregulated miRNAs in MetS compared to non-Met patients (<i>p</i> < 0.05). In silico studies revealed three miRNAs (miR-155, miR-181a, and let-7a) and their predictive targets (CCAAT/enhancer-binding protein beta—<i>CEBPB</i>, KRAS proto-oncogene, GTPase—<i>KRAS</i> and suppressor of cytokine signaling 1—<i>SOCS1</i>) with a potential role in the insulin receptor signaling pathway. miR-155 expression was reduced and <i>CEBPB</i> mRNA levels were increased in MetS patients (<i>p</i> < 0.05), and these effects were correlated with the number of MetS diagnostic criteria (<i>p</i> < 0.05). Increased HOMA-IR (>7.6) was associated with low miR-155 levels, high <i>CEBPB</i> expression, and serum hsCRP (<i>p</i> < 0.05). miR-155 was negatively correlated with <i>CEBPB</i>, HOMA-IR, and plasma fibrinogen, and positively correlated with serum adiponectin (<i>p</i> < 0.05). Downregulation of circulating miR-155 is associated with insulin resistance, poor glycemic control, and increased MetS-related cardiometabolic risk, and these effects are potentially mediated by interaction with <i>CEBPB.</i>https://www.mdpi.com/1422-0067/22/3/1468obesitymetabolic syndromemicroRNAsmiR-155<i>CEBPB</i>cardiometabolic risk